| The influence of cost‐effectiveness and other factors on nice decisions H Dakin, N Devlin, Y Feng, N Rice, P O'neill, D Parkin Health economics 24 (10), 1256-1271, 2015 | 283 | 2015 |
| The trajectory of dementia in the UK-making a difference F Lewis, S Karlsberg Schaffer, J Sussex, P O’Neill, L Cockcroft Office of Health Economics Consulting Reports 2013, 1-55, 2014 | 138 | 2014 |
| Comparing access to orphan medicinal products in Europe B Zamora, F Maignen, P O’Neill, J Mestre-Ferrandiz, M Garau Orphanet Journal of Rare Diseases 14, 1-12, 2019 | 90 | 2019 |
| Shedding the pounds: obesity management, NICE guidance and bariatric surgery in England P O’Neill Monograph, 2010 | 29 | 2010 |
| An analysis of NICE’s ‘restricted’(or ‘optimized’) decisions P O’Neill, NJ Devlin Pharmacoeconomics 28, 987-993, 2010 | 25 | 2010 |
| International comparison of medicines usage: quantitative analysis P O’neill, J Sussex Office of Health Economics and the Association of the British Pharmaceutical …, 2014 | 17 | 2014 |
| Realising the broader value of vaccines in the UK S Brassel, M Neri, P O'Neill, L Steuten Vaccine: X 8, 100096, 2021 | 13 | 2021 |
| Projecting expenditure on medicines in the UK NHS P O’Neill, J Mestre-Ferrandiz, R Puig-Peiro, J Sussex PharmacoEconomics 31, 933-957, 2013 | 11 | 2013 |
| Barriers to uptake of minimal access surgery in the united kingdom A Cole, P O’Neill, C Sampson, P Lorgelly OHE Consulting Report, London: Office of Health Economics, 2018 | 10 | 2018 |
| R&D, competition and diffusion of innovation in the EU: the case of Hepatitis C M Berdud, M Garau, M Neri, P O’Neill, C Sampson, A Towse OHE research paper 18 (06), 2018 | 9 | 2018 |
| Improving efficiency and resource allocation in future cancer care A Cole, A Lundqvist, P Lorgelly, H Norrlid, S Karlsberg Schaffer, F Lewis, ... Consulting Reports, 2016 | 7 | 2016 |
| The trajectory of dementia in the UK-making a difference. Office of Health Economics Consulting Reports F Lewis, S Karlsberg Schaffer, J Sussex, P O’Neill, L Cockcroft | 7 | 2014 |
| NICE's cost-effectiveness threshold revisited: new evidence on the influence of cost-effectiveness and other factors on NICE decisions N Devlin, H Dakin, N Rice, D Parkin, P O'Neill Value in Health 13 (7), 2010 | 7 | 2010 |
| The trajectory of dementia in the UK-making a difference; 2014 F Lewis, SK Schaffer, J Sussex, P O’Neill, L Cockcroft Q17, 2020 | 6 | 2020 |
| The influence of cost-effectiveness and other factors on NICE decisions. HERC Research Paper 01/13 H Dakin, N Devlin, Y Feng, N Rice, P O’Neill, D Parkin Health Economics Research Centre, University of Oxford, 2014 | 6 | 2014 |
| Does NICE influence the adoption and uptake of generics in the UK? V Serra-Sastre, S Bianchi, J Mestre-Ferrandiz, P O’Neill The European Journal of Health Economics 22, 229-242, 2021 | 5 | 2021 |
| Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries B Zamora, F Maignen, PO Neill, J Mestre-Ferrandiz, M Garau OHE Consulting Report, 1-37, 2017 | 5 | 2017 |
| The Impact of New Medicines in the NHS: 70 Years of Innovation C Sampson, P O’Neill, P Lorgelly OHE Consulting Report, 2018 | 4 | 2018 |
| OP138 access to orphan drugs in the United Kingdom and other European countries B Zamora, M Garau, F Maignen, P O'Neill, J Mestre-Ferrandiz International Journal of Technology Assessment in Health Care 33 (S1), 64-65, 2017 | 3 | 2017 |
| International Comparisons of Medicine Prices: 2011 Indices P O’Neill, R Puig-Peiró, J Mestre-Ferrándiz, J Sussex Office of Health Economics, 2012 | 3 | 2012 |
